Comparison of the echinocandin caspofungin with amphotericin b for treatment of Histoplasmosis following pulmonary challenge in a murine model

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 7, 2000, Pages 1850-1854

  Kohler, Steve ^a,b   Wheat, L Joseph ^a,b,c,d   Connolly, Patricia ^b,c   Schnizlein Bick, Carol ^c   Durkin, Michelle ^b,c   Smedema, Melinda ^b,c   Goldberg, Janet ^b,c   Brizendine, Edward ^c  

^a RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Department of Medicine ^*  (United States)

^d Histoplasmosis Reference Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FUNGUS ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ANTIGEN DETECTION; ARTICLE; BODY BURDEN; CONCENTRATION RESPONSE; CONTROLLED STUDY; FUNGICIDAL ACTIVITY; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; LUNG; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; STRAIN DIFFERENCE;

EID: 0033934972     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.7.1850-1854.2000     Document Type: Article

References (19)

1. Abruzzo, G. K., A. M. Flattery, C. J. Gill, L. Kong, J. G. Smith, D. Krupa, V. B. Pikounis, H. Kropp, and K. Bartizal. 1995. Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob. Agents Chemother. 39:1077-1081.
2. Bartizal, K., C. J. Gill, G. K. Abruzzo, A. M. Flattery, L. Kong, P. M. Scott, J. G. Smith, C. E. Leighton, A. Bouffard, J. F. Dropinski, and J. Balkovec. 1997. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41:2326-2332.
3. Bartizal, K., T. Scott, G. K. Abruzzo, C. J. Gill, C. Pacholok, L. Lynch, and H. Kropp. 1995. In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373. Antimicrob. Agents Chemother. 39:1070-1076.
4. o derivatives. J. Med. Chem. 37: 222-225.
5. Connolly, P., J. Wheat, C. Schnizlein-Bick, M. Durkin, S. Kohler, M. Smedema, J. Goldberg, E. Brizendine, and D. Loebenberg. 1999. Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob. Agents Chemother. 43:322-328.
6. Conover, W. J., and R. L. Iman. 1981. Rank transformations as a bridge between parametric and nonparametric statistics. Am. Stat. 35:124-129.
7. Durkin, M. M., P. A. Connolly, and L. J. Wheat. 1997. Comparison of radioimmunoassay and enzyme-linked immunoassay methods for detection of Histoplasma capsulatum var. capsulatum antigen. J. Clin. Microbiol. 35: 2252-2255.
8. Franzot, S. P., and A. Casadevall. 1997. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob. Agents Chemother. 41:331-336.
9. Graybill, J. R., R. Bocanegra, M. Luther, A. Fothergill, and M. J. Rinaldi. 1997. Treatment of murine Candida krusei or Candida glabrata infection with L-743,872. Antimicrob. Agents Chemother. 41:1937-1939.
10. Graybill, J. R., L. K. Najvar, M. F. Luther, and A. W. Fothergill. 1997. Treatment of murine disseminated candidiasis with L-743,872. Antimicrob. Agents Chemother. 41:1775-1777.
11. Graybill, J. R., L. K. Najvar, E. M. Montalbo, F. J. Barchiesi, M. F. Luther, and M. G. Rinaldi. 1998. Treatment of histoplasmosis with MK-991 (L-743,872). Antimicrob. Agents Chemother. 42:151-153.
12. Hajdu, R., R. Thompson, J. G. Sundelof, B. A. Pelak, F. A. Bouffard, J. F. Dropinski, and H. Kropp. 1997. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41:2339-2344.
13. Krishnarao, T. V., and J. N. Galgiani. 1997. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother. 41:1957-1960.
14. Kurtz, M. B., E. M. Bernard, F. F. Edwards, J. A. Marrinan, J. Dropinski, C. M. Douglas, and D. Armstrong. 1995. Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis. Antimicrob. Agents Chemother. 39:1784-1789.
15. Kurtz, M. B., C. Douglas, J. Marrinan, K. Nollstadt, J. Onishi, S. Dreikorn, J. Milligan, S. Mandala, J. Thompson, J. M. Balkovec, F. A. Bouffard, J. F. Dropinski, M. L. Hammond, R. A. Zambias, G. Abruzzo, K. Bartizal, O. B. McManus, and M. L. Garcia. 1994. Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis. Antimicrob. Agents Chemother. 38:2750-2757.
16. Schmatz, D. M., M. A. Powles, D. McFadden, K. Nollstadt, F. A. Bouffard, J. Dropinski, P. Liberator, and J. Anderson. 1995. New semisynthetic pneumocandins with improved efficacies against Pneumocystis carinii in the rat. Antimicrob. Agents Chemother. 39:1320-1323.
17. Vazquez, J. A., M. Lynch, D. Boikov, and J. D. Sobel. 1997. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob. Agents Chemother. 41:1612-1614.
18. Waitz, J. A., M. S. Bartlett, M. A. Ghannoum, A. Espinel-Ingroff, M. V. Lancaster, F. C. Odds, M. A. Pfaller, J. H. Rex, M. G. Rinaldi, T. J. Walsh, and J. N. Galgiani. 1997. Reference method of broth dilution antifungal susceptibility testing of yeasts, p. 1-29. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
19. Worsham, P. L., and W. E. Goldman. 1988. Selection and characterization of ura5 mutants of Histoplasma capsulatum. Mol. Gen. Genet. 214:348-352.